Special Issue

Carbapenem-Resistant Enterobacterales: Development of New Antibiotics

Message from the Guest Editor

Carbapanem-resistant Enterobacteriaceae (CRE) represents a serious threat for public health and a challenge for clinicians. CRE are often resistant to multiple antimicrobials and antimicrobial options available against theese microrganisms are limited. Recently, novel □-lactams/□-lactamase inhibitor combinations (□L-□LICs) have been developed for the treatment of DTR infections resulting from CRE pathogens. These novel molecules represent a promising tool to counteract CRE infections and limit diffusione of MDR microrganisms. This Special Issue is dedicated to research on novel antimicrobials againts CRE, including novel approaches to optimizing antimcirobial treatments, characterization of new traits of resistance and the epidemiology of susceptiblity patterns.

Guest Editor

Dr. Paolo Gaibani
IRCCS Azienda-Ospedaliera, Universitaria di Bologna, Bologna, Italy

Deadline for manuscript submissions

closed (31 December 2023)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/137264

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI